Stock price movements
On February 15, Boston Scientific (BSX) closed at $40.01, 0.23% higher than its previous closing price, 52.30% higher than its 52-week low of $26.27, and 0.79% below its 52-week high of $40.33. Its market capitalization was $55.24 billion, and its trailing-12-month and forward PE ratios are 33.74x and 22.18x, respectively.
Since its fourth-quarter earnings release on February 6, Boston Scientific stock has increased by 5.65% from $37.75 on February 5 to $40.01 on February 15. The company surpassed its consensus EPS estimate by $0.03 in the fourth quarter.
On February 15, Abbott Laboratories (ABT) closed at $75.25, 1.73% higher than its previous closing price, 32.46% higher than its 52-week low of $56.81, and 0.03% below its 52-week high of $75.27. Its market capitalization was $132.41 billion, and its trailing-12-month and forward PE ratios are 53.90x and 20.91x, respectively.
Since its fourth-quarter earnings release on January 23, Abbott Laboratories stock rose by 5.26% from $71.49 on January 22 to $75.25 on February 15. The company surpassed its consensus revenue estimate by $40 million. Boston Scientific is trading at a lower trailing PE ratio but a higher forward PE ratio as compared to Abbott Laboratories.
Analysts’ recommendations and target price
The 12-month consensus recommendation for Boston Scientific and Abbott Laboratories is a “strong buy” and a “buy,” respectively. Of the 24 analysts covering Boston Scientific, 15 recommend a “strong buy,” seven recommend a “buy,” and two recommend a “hold.” Their 12-month target price is $43.8, 9.47% higher than its last closing price on February 15. The highest target price estimate for the company is $48, and the lowest is $39.5.
On the other hand, eight analysts rated Abbott Laboratories as a “strong buy,” 11 have rated it as a “buy,” while only two have rated the company as a “hold.” Analysts’ 12-month target price for Abbott Laboratories is $80.08, 6.42% higher than its last closing price on February 15. The highest and the lowest target price estimate for the company is $86 and $70, respectively.
Next, we’ll look at the revenue growth trajectory of Boston Scientific and Abbott Laboratories in greater detail.